Helsinn, Chugai deal

Helsinn granted Chugai’s Chugai Pharma Marketing Ltd. subsidiary exclusive commercialization rights to NEPA in the U.K. and Ireland and, starting in 2015, to palonosetron as monotherapy in the U.K. N...